Rain Oncology Inc to Discuss the Topline Data from Phase 3 MANTRA Trial Call Transcript
Greetings, and welcome to the Rain Oncology Phase III Topline Results Data Call. (Operator Instructions) As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Dan Ferry, Managing Director of LifeSci Advisors. Please go ahead, sir.
Thank you, operator. Good morning, and thank you for joining us on the conference call to discuss the topline results of Rain's Phase III MANTRA trial of milademetan in dedifferentiated liposarcoma. On the call with me today are Avanish Vellanki, Co-Founder, Chairman and Chief Executive Officer of Rain Oncology; Dr. Robert Doebele, Co-Founder and Chief Scientific Officer; Dr. Richard Bryce, Chief Medical Officer; and Nelson Cabatuan, SVP of Finance.
Earlier this morning, Rain issued a press release with topline data from the Phase III MANTRA study. This release is accessible in the News and Press Releases section of Rain's website at www
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |